Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: Single center experience with 10 cases and review of the literature

Daniel Pink(Universitätsmedizin Greifswald), Peter Reichardt(Helios Hospital Berlin-Buch), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Bernd Dörken(Charité - Universitätsmedizin Berlin), Tanja Lindner(Helios Hospital Berlin-Buch), A. Mrozek(Helios Hospital Berlin-Buch), Albrecht Kretzschmar(Roche (Switzerland))

Gynecologic Oncology

December 22, 2005

10.1016/j.ygyno.2005.11.010

Cited by 177

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.6k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

|Journal of Clinical Investigation|1997|765

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|751